Survey of HCMV in allogenic and autologous stem cell transplantation by real-time PCR in Kermanshah, west of Iran
Open Access
- 2 February 2021
- journal article
- research article
- Published by Springer Nature in Infectious Agents and Cancer
- Vol. 16 (1) , 1-7
Abstract
Introduction: Human Cytomegalovirus (HCMV) is the most important viral pathogen in people undergoing bone marrow transplantation (BMT). HCMV detection in the early stages makes is possible to save the patients’ lives through immediate and timely treatment. The aim of this study was to investigate the status of HCMV using the real-time PCR method in BMT patients in Kermanshah, west of Iran. Methods: HCMV monitoring was done in 120 patients who underwent BMT, 38 allogeneic cases and 82 autologous cases, using the ELISA serology test before transplantation. The participants were followed up 100 days after transplantation for HCMV detection in blood samples using real-time PCR. Preemptive therapy started with Ganciclovir and Foscarnet when the viral load was > 200 HCMV DNA copies/ml. Results: Despite preemptive therapy, infection recurred in less than 1 month. HCMV recurred more frequently in patients undergoing allogenic transplation versus those receiving autologous transplantation. Recurrence was seen in 5 patients receiving allogenic transplantation. HCMV recurrence occurred in five patients with allogeneic transplantation. Twelve patients undergoing allogeneic or autologous transplantation (83%) and a virus load of > 1000 copies/ml showed HCMV-related symptoms. Three patients died, two due to HCMV-related pneumonia and the other one due to a fungal infection. Conclusion: Real-time PCR may be a useful method for quantification and monitoring of HCMV recurrence and may be helpful in choosing more efficient HCMV preemptive treatment in BMT recipients.Keywords
This publication has 47 references indexed in Scilit:
- Clinical Significance of Low Cytomegalovirus DNA Levels in Human PlasmaJournal of Clinical Microbiology, 2012
- Intensive strategy to prevent CMV disease in seropositive umbilical cord blood transplant recipientsBlood, 2011
- Cytomegalovirus in Hematopoietic Stem Cell Transplant RecipientsHematology/Oncology Clinics of North America, 2011
- Quality and Safety in Blood Supply in 2010Transfusion Medicine and Hemotherapy, 2010
- Human Cytomegalovirus (HCMV) – RevisedTransfusion Medicine and Hemotherapy, 2010
- Long-Term Outcomes of CMV Disease Treatment with Valganciclovir Versus IV Ganciclovir in Solid Organ Transplant RecipientsAmerican Journal of Transplantation, 2009
- Prediction of Cytomegalovirus (CMV) Plasma Load from Evaluation of CMV Whole-Blood Load in Samples from Renal Transplant RecipientsJournal of Clinical Microbiology, 2008
- Idarubicin Containing Regimen in Multiple Myeloma: Preliminary Results of a Pilot Study Using a Modified "TANDEM" Transplant ProgramLeukemia & Lymphoma, 2003
- Prevention of Cytomegalovirus Disease in Hematopoietic Stem Cell TransplantationClinical Infectious Diseases, 2002
- High frequency of positive surveillance for cytomegalovirus (CMV) by PCR in allograft recipients at low risk of CMVBone Marrow Transplantation, 2001